Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc

Austal ( ($AU:ASB) ) has shared an announcement. Austal Limited has announced that State Street Corporation and its subsidiaries have ceased to be ...

State Street Corporation Ceases Substantial Holding in Austal Limited

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Autolus Therapeutics yesterday and set a price target of $5.00. The company’s shares close...

Wells Fargo Sticks to Its Buy Rating for Autolus Therapeutics (AUTL)

The latest announcement is out from Austal ( ($AU:ASB) ). Austal Limited has announced that State Street Corporation and its subsidiaries have ceas...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUTL	$1.61	+1.26%	3.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUTL	$1.61	+1.3%	3.44M
3
4
5
6

AUTL

AUTL

Get Autolus Therapeutics plc Data in Excel

Get Autolus Therapeutics plc Data in Excel